论文部分内容阅读
目的观察顺铂治疗非小细胞肺癌的临床效果及药物安全性。方法选择2013年6月-2015年6月医院治疗的非小细胞肺癌患者86例分为观察组和对照组各43例。对照组采用伊利替康治疗,观察组采用伊利替康联合顺铂治疗,观察2组患者的治疗效果和不良反应的发生率。结果观察组总有效率为60.47%高于对照组的37.21%,差异有统计学意义(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论顺铂与伊利替康联合治疗晚期非小细胞肺癌,能够有效提高治疗效果,且不良反应未见明显增加,值得在临床上推广使用。
Objective To observe the clinical efficacy and safety of cisplatin in the treatment of non-small cell lung cancer. Methods Sixty-six patients with non-small cell lung cancer (NSCLC) treated in our hospital from June 2013 to June 2015 were divided into observation group (43 cases) and control group (43 cases). The control group was treated with irinotecan, and the observation group was treated with irinotecan and cisplatin. The therapeutic effect and the incidence of adverse reactions in the two groups were observed. Results The total effective rate of the observation group was 60.47% higher than that of the control group (37.21%), the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Combination of cisplatin and irinotecan in the treatment of advanced non-small cell lung cancer, can effectively improve the treatment effect, and no significant increase in adverse reactions, it is worth promoting in clinical use.